Connect with us

Technology

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

Published

on

PALO ALTO, Calif., May 29, 2024 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences:

Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT), New York, New YorkGoldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT), Miami Beach, Florida

A live webcast of both presentations will be available on the “Events and Presentations” section of Kodiak’s website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.

In addition, Kodiak will participate in the upcoming Clinical Trials at the Summit 2024 meeting, being held on June 8 from 8:00am5:30pm (MT) in Park City, Utah. Presentations on Kodiak’s clinical pipeline will be given at the meeting. Specifics of the presentations are below:

Title: Bispecific Anti-IL-6 Anti-VEGF Programs: KSI-501 in Retinal Vascular Disease and KSI-101 in Macular Edema Secondary to Inflammation
Time: 7:49 – 7:53 AM MT
Presenter: Quan Dong Nguyen, M.D., Professor of Ophthalmology and Director of Uveitis and Ocular Inflammation, Byers Eye Institute, Stanford University School of Medicine.

Title: Update on KSI Programs for Retinal Diseases
Time: 1:10 – 1:14 PM MT
Presenter: Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences

Slides of these presentations will be made available on the “Events and Presentations” section of Kodiak’s website at http://ir.kodiak.com/ at the beginning of the presentations.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak’s discovery engine. We are developing a portfolio of three clinical programs, two of which are late-stage today and derived from our ABC Platform and one which is platform-independent and which we believe can progress rapidly into pivotal studies.

Kodiak’s lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases including diabetic retinopathy, the leading cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world.

KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting multiple disease biologies for differentiated efficacy. Phase 1b data for KSI-501 was presented in February 2024, and the Phase 3 DAYBREAK study of KSI-501 in wet AMD is scheduled to be actively screening patients in mid-2024.

Additionally, Kodiak is developing a third product candidate, KSI-101, a novel anti-IL-6, VEGF-trap bispecific protein, the unconjugated protein portion of KSI-501. Kodiak intends to develop KSI-101 for the treatment of retinal inflammatory diseases, as currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina.

Kodiak has expanded its early research pipeline of duet and triplet inhibitors that embed small molecules and other active pharmaceutical ingredients (“API”) in the biopolymer backbone to enable targeted, high drug-antibody ratio (“DAR”) medicines. The diverse API’s are designed to be released over time to achieve targeted, multi-specific and tailored modulation of biological pathways. The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial ophthalmic and systemic diseases.

For more information, please visit www.kodiak.com.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-investor-and-clinical-conferences-302158588.html

SOURCE Kodiak Sciences Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

LICC Invites Int’l Students to Showcase Their Chinese Talents via Short Videos

Published

on

By

SHENYANG, China, May 9, 2025 /PRNewswire/ — Recently, the “Show Your Chinese Talents—International Interactive Communication Project for International Students in Liaoning to Display Chinese Talents”, planned by the Liaoning International Communication Center in China, has been officially launched. The project focuses on “Generation Z” international students in Liaoning Province, seeking out “foreign talents” from all over the world who have mastered traditional Chinese arts through active learning. Their learning experiences, achievements, and sharing of Chinese culture are recorded via short videos, showcasing the unique charm of China’s excellent traditional culture in an all-round way.

Young students from various countries studying in Liaoning not only learn Chinese language and specialized knowledge but also have a strong passion for traditional Chinese culture in their daily learning. Universities in the province have elaborately designed traditional Chinese cultural courses for international students, such as Beijing (or Peking) Opera, Chinese calligraphy and Taiji (or Tai Chi), and cultivated plenty of “foreign talents”. The project hunts for international students who are nationally representative, and have superb Chinese talents, and selects excellent traditional Chinese cultural projects for filming and promotion, such as Chinese martial arts, guqin (a seven-stringed zither), Beijing Opera and Chinese calligraphy. The cultural projects boast Liaoning’s distinctive regional characteristics, and fully reflect the essence of Chinese culture, drawing the active participation of young people from all over the world.

Featuring international students in Liaoning, the short videos unfold the grace of traditional Chinese culture from the perspective of “Generation Z”, comprehensively revealing the international communication value of traditional Chinese culture, and fostering a deeper understanding of Chinese culture among overseas viewers.

The series of short videos, all shot in full 4K high definition, has been released, presenting viewers with a visual feast that is stylish, profound and memorable. After being posted on overseas social media platforms, the videos have attracted young people from all over the world to admire Chinese culture and experience the integration and harmony of diverse cultures together. This has further aroused a new understanding and perception of “a community with a shared future for mankind”.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/licc-invites-intl-students-to-showcase-their-chinese-talents-via-short-videos-302450958.html

SOURCE Liaoning International communication Center(LICC)

Continue Reading

Technology

Take the Tide and Forge Ahead: Pylontech Unveils New C&I Energy Storage Solutions at Intersolar 2025

Published

on

By

MUNICH, May 9, 2025 /CNW/ — At Intersolar Europe 2025, Pylontech (SHSE:688063), a global leader in energy storage sector, unveiled its next-generation liquid-cooled systems tailored for the rapidly growing commercial and industrial (C&I) energy storage market in Europe.

As a pioneer and leader in residential energy storage, Pylontech has built a strong global brand presence, supported by its vertically integrated R&D and manufacturing capabilities—from core cell technology to complete system integration. In response to the growing demand from the commercial and industrial (C&I) sector, Pylontech has significantly expanded its product portfolio in recent years. At this year’s event, the company unveiled the liquid-cooled L2200 OMNI and L3300 BAT—safe, reliable, and high-performance energy storage solutions tailored to meet the evolving needs of the market.

The L2200 OMNI is an all-in-one containerized system that integrates PCS, transformer, EMS, and fire protection—offering a plug-and-play solution with simplified deployment and minimized commissioning time. The system features comprehensive safety mechanisms and supports a 1C rate, delivering robust performance. The L3300 BAT is a battery-only system, providing flexibility for diverse applications. Both solutions are engineered for high safety, fast deployment, and strong performance with high C rate. They are certified to major international standards including IEC, VDE, and UN38.3 and more, underscoring Pylontech’s commitment to global compliance and market readiness.

In parallel, Pylontech released a joint white paper with TÜV Rheinland titled “High Environmental Adaptability for Commercial and Industrial Liquid-Cooling Battery Energy Storage Systems.” The paper addresses the need for stable system performance in environments subject to temperature fluctuations, humidity changes, vibrations, and spatial constraints, etc. and offers insights and practices for tackling these challenges.

“Over the past decade, we have been proud to play an active role in the energy storage industry and witnessed its significant role in shaping the future of energy,” said Geoffrey Song, Vice President of Pylontech. “In Europe, the demand from the commercial and industrial sectors is rapidly increasing. We are dedicated to providing the solutions our customers need, remaining a reliable partner and collaborating with industry peers to build a more sustainable future.”

View original content to download multimedia:https://www.prnewswire.com/news-releases/take-the-tide-and-forge-ahead-pylontech-unveils-new-ci-energy-storage-solutions-at-intersolar-2025-302450960.html

SOURCE Pylontech

Continue Reading

Technology

Ex-Perkbox CEO Gautam Sahgal Partners with CSMA to Invest in and Scale Parliament Hill

Published

on

By

LONDON, May 8, 2025 /PRNewswire/ — Gautam Sahgal, former CEO of leading employee engagement platform Perkbox, has partnered with CSMA to invest in and further develop Parliament Hill, the UK’s leading provider of membership association benefits platforms.

As part of this strategic partnership, Gautam Sahgal and CSMA will jointly invest in the continued growth of Parliament Hill, focusing on advancing its technology, expanding its commercial offering, and scaling its impact across the membership sector.

Sahgal, who has been appointed Executive Chairman of Parliament Hill, brings a strong track record of building and transforming businesses. He previously led Perkbox through a period of international expansion and product development. Perkbox was subsequently acquired by Great Hill Partners in June 2024. Prior to his time at Perkbox, Gautam successfully turned around Thomsonlocal, saving it from liquidation and transforming it into a digital listings business.

Joining him as CEO of Parliament Hill is Joel Tobias, a seasoned executive with over 20 years of experience in the benefits, rewards, gift card, and affiliate marketing sectors. His leadership roles have included senior positions at Perkbox, LifeWorks, NextJump, and NetVoucherCodes, bringing deep commercial and operational expertise to drive the next phase of Parliament Hill’s growth.

Gautam Sahgal, Executive Chairman of Parliament Hill, said:
“I’m delighted to bring my experience to Parliament Hill at such a pivotal moment. Membership associations face increasing pressure to acquire, engage, and retain their members — and the key to doing so is by delivering real, tangible value. These are unique, targeted audiences who need a universal product that works for all, but also tailored, bespoke solutions that speak directly to their needs. The scale we’re starting with — over 6 million users — is truly exciting and gives us a strong foundation to build something market-leading.”

Joel Tobias, CEO of Parliament Hill, added:
“This is an incredible opportunity to reimagine the role of member benefits. Our ambition is to build a platform that’s modern, agile, and focused on the specific needs of the membership organisations we serve — offering them world-class engagement tools and unrivalled value for their members.”

Colin Slinn, CEO of CSMA, commented:
“CSMA acquired Parliament Hill in 2018 and we’re thrilled to partner with Gautam and Joel to invest further in its future. With the right leadership, resources, and strategy, we’re confident Parliament Hill will become an even stronger force in the membership space.”

Through this partnership, Parliament Hill will accelerate innovation in benefits technology, curate an expanded range of offers tailored to diverse member needs and strengthen its position as the go-to platform for membership organisations looking to deliver exceptional value.

About CSMA
CSMA is the parent company of Boundless, a membership organisation dedicated to helping current and former public sector workers make the most of their free time, offering access to exclusive deals, events, experiences, and benefits for over 100 years. For more information, please visit www.boundless.co.uk.

About Parliament Hill

Parliament Hill is the UK’s market leader in building and managing benefits platforms for professional membership associations, serving over 6.2 million members across a wide range of industries. For more information, please visit www.parliament-hill.co.uk

Logo: https://mma.prnewswire.com/media/2683440/Parliament_Hill_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ex-perkbox-ceo-gautam-sahgal-partners-with-csma-to-invest-in-and-scale-parliament-hill-302450966.html

Continue Reading

Trending